Ayhan AKÖZ, Serhat ORUN, Mücahit AVCİL, ALİ DUMAN, Kenan Ahmet TÜRKDOĞAN

A fatal dermatosis in the emergency department: toxic epidermal necrolysis

Toxic Epidermal Necrolysis (TEN) is a life-threatening dermatosis, which are mainly induced by drugs. The mortality rate and incidence of TEN is 20-30% and 0.5-1.2 cases per million population annualy. Drug hypersensitivity is very important in the development of it. Antimicrobials and anticonvulsants are most frequently associated with the development of it. TEN is a disease which acutely starts and has prodromes such as cough lasting 1-3 days, throat ache, burning eyes, arthralgia before the disease. Intraoral erosion is a constant result. Sepsis and respiratory insufficiency were the most important complications in TEN. The main therapy are drugs used by the patient were stopped, systemic corticosteroid and supportive treatment. The aim of our study is recognized of TEN by emergency physicians

PDF

___

Thomas JJ, Person AD, Brady WJ. Serius Generalized Skin Disorders. In: Tintinalli JE. editor. Tintinalli's Emergency Medicine: A Compherensive Study Guide, 7th ed. Istanbul: Nobel Medical. 2013; p. 1615-17.

Kangal H, Gulez P, Hekimoglu U, Hizarcioglu M. Toxic epidermal necrolysis-Stevens Johnson overlap syndrome: A case report Izmir Dr. Behçet Uz Pediatric Hospital Journal. 2012;2(1):32-5.

Altas M, Aras M, Yılmaz A, Sarikaya G, Urfali B, Serarslan Y, Yilmaz N. Toxic Epidermal Necrolysis After Prophylactic Antibiotic Use. Kocatepe Medical Journal. 2012;13(2):103-6.

Allanore V, Roujeau JC. Epidermal necrolysis (Stevens- Johnson syndrome and toxic epidermal necrolysis). In: Wolff K, Goldsmith L, Katz S, eds, Fitzpatrick's Dermatology in General Medicine, 7th ed. New York, NY: McGraw-Hill. 2008; 349-55.

Unal G. Dermatological emergencies Cerrahpaşa J Med. 2002;33(2):132-7.

Zhang Y, Wang J, Zhao LM, Peng W, Shen GQ, Xue L, Zheng XX, He XJ, Gong CY, Miao LY. Strong association between HLA-B*1502 syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol. 2011;67(9):885-7. Stevens-Johnson

Honma M, Tobisawa S, Iinuma S, Shibuya T, Komatsu S, Takahashi I, Ishida-Yamamoto A, Iizuka H. Toxic epidermal necrolysis with prominent facial pustules: a case with reactivation of human herpesvirus 7. Dermatology. 2010;221(4):306-8.

Lalosevic J, Nikolic M, Gajic M, Skiljevic D, Medenica L. Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20- year single-center experience. Int J Dermatol. 2015;54(8):978-84.

Zajicek R, Pintar D, Broz L, Suca H, Königova R. Toxic epidermal necrolysis and Stevens-Johnson syndrome at the Prague Burn Centre 2012;26(5):639-43. Acad Dermatol Venereol.

Yamane Y, Aihara M, Tatewaki S, Matsukura S, Kanbara T, Yamakawa Y, Ikezawa Z. Analysis of treatments and deceased cases of severe adverse drug reactions - analysis of 46 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Jpn J Allergol. 2009;58(5):537-47.

Guillaume JC, Roujeau JC, Revuz J, Pnso D, Touraine R. The cuiprit drugs in 87 cases of toxic epidermal necrolysis (Lyell syndrome).Arch Dermatol. 1987;123(9):1166-70.

Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp Rev Clin Immunol. 2011;7(6):803-13.

Struck MF, Hilbert P, Mockenhaupt M, Reichelt B, Steen M. Severe cutaneous adverse reactions: emergency approach to non- burn 2010;36(1):22-32. Intensive Care Med.

Mockenhaupt M. Severe drug induced skin reactions: clinical pattern, diagnostic and therapy. J. Dtsch. Dermatol Ges. 2009;7(2):142-63.

Downey A, Jackson C, Harun N, Cooper A. Toxic epidermal necrolysis: review of pathogenesis and management. J Am Acad Dermatol. 2012 66(6):995-1003.